Vanderbilt investigators have developed a new mouse model of kidney fibrosis, which provides a platform for identifying new targets and treatment strategies.

Vanderbilt investigators have discovered a class of compounds that inhibit a mediator of inflammation and autoimmune disorders, and that could pave the way for development of future therapies.

Scott Smith, M.D., Ph.D., assistant professor of Medicine, has received a 2017 research award from the Stanley Cohen Innovation Fund to test a new therapeutic strategy for peanut allergies. Smith's research could fundamentally change allergy treatment.

Researchers in the Vanderbilt Institute for Global Health (VIGH) have received two new grants from the National Institutes of Health (NIH) aimed at reducing the risk of kidney disease in HIV-infected adults and improving the treatment of epilepsy in children in Nigeria.

Nine more volunteers are needed to complete a study at Vanderbilt University Medical Center (VUMC) that could lead to a way to prevent the spread of HIV (human immunodeficiency virus).

Nashville Mayor Megan Barry will speak during a “science day,” Tuesday, Oct. 17, at the Belcourt Theatre hosted by the Vanderbilt Center for Addiction Research (VCAR).

A compound identified at Vanderbilt represents a new lead for treating rare, aggressive childhood cancers called Ewing sarcomas.